1. Home
  2. CAPR vs CPAC Comparison

CAPR vs CPAC Comparison

Compare CAPR & CPAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • CPAC
  • Stock Information
  • Founded
  • CAPR 2005
  • CPAC 1949
  • Country
  • CAPR United States
  • CPAC Peru
  • Employees
  • CAPR N/A
  • CPAC N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • CPAC Building Materials
  • Sector
  • CAPR Health Care
  • CPAC Industrials
  • Exchange
  • CAPR Nasdaq
  • CPAC Nasdaq
  • Market Cap
  • CAPR 600.7M
  • CPAC 493.6M
  • IPO Year
  • CAPR N/A
  • CPAC 2012
  • Fundamental
  • Price
  • CAPR $9.72
  • CPAC $5.82
  • Analyst Decision
  • CAPR Strong Buy
  • CPAC Sell
  • Analyst Count
  • CAPR 8
  • CPAC 2
  • Target Price
  • CAPR $33.75
  • CPAC $6.20
  • AVG Volume (30 Days)
  • CAPR 3.3M
  • CPAC 3.1K
  • Earning Date
  • CAPR 08-06-2025
  • CPAC 07-21-2025
  • Dividend Yield
  • CAPR N/A
  • CPAC 8.49%
  • EPS Growth
  • CAPR N/A
  • CPAC 15.59
  • EPS
  • CAPR N/A
  • CPAC 0.13
  • Revenue
  • CAPR $17,363,588.00
  • CPAC $545,786,617.00
  • Revenue This Year
  • CAPR $258.96
  • CPAC N/A
  • Revenue Next Year
  • CAPR $8.02
  • CPAC N/A
  • P/E Ratio
  • CAPR N/A
  • CPAC $9.28
  • Revenue Growth
  • CAPR N/A
  • CPAC 2.78
  • 52 Week Low
  • CAPR $3.52
  • CPAC $5.10
  • 52 Week High
  • CAPR $23.40
  • CPAC $6.65
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 45.24
  • CPAC 56.21
  • Support Level
  • CAPR $6.07
  • CPAC $5.87
  • Resistance Level
  • CAPR $11.58
  • CPAC $6.00
  • Average True Range (ATR)
  • CAPR 1.59
  • CPAC 0.09
  • MACD
  • CAPR -0.23
  • CPAC -0.00
  • Stochastic Oscillator
  • CAPR 44.57
  • CPAC 81.44

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About CPAC Cementos Pacasmayo S.A.A. (Each representing five)

Cementos Pacasmayo SAA is a Peruvian cement company that produces, distributes, and sells cement and cement-related materials, such as concrete blocks and ready-mix concrete. The company's products are used in construction. It also produces and sells quicklime for use in mining operations. The company sells its products mainly in the northern part of Peru. It owns three cement production and transportation facilities. Its flagship Pacasmayo facility is located in the northwest region of Peru, while its new cement plant in Piura and smaller Rioja facility are located in the northeast region of Peru.

Share on Social Networks: